Agilon Health reported second-quarter revenue of approximately $1.5 billion, medical margin of $197 million, and adjusted EBITDA of $70 million, exceeding guidance and reversing prior-year losses of $53 million and $83 million respectively. The company raised its 2026 outlook to roughly $5.8 billion in revenue, $485 million in medical margin, and $85 million in adjusted EBITDA. The improvements were driven by stronger risk-adjustment revenue and favorable medical-cost trends, despite lower Medicare Advantage membership. Medicare Advantage membership stood at 437,000 at quarter-end, down from 498,000 a year earlier but up from 426,000 in the first quarter. CEO Tim O'Rourke emphasised operational consistency and clinical programmes for conditions including heart failure, COPD, and dementia, whilst prioritising growth in existing markets.

Healthcare services company Agilon Health reported second-quarter 2026 revenue of $1.49 billion, beating analyst estimates of $1.45 billion and representing 7.2% year-on-year growth. The company also exceeded expectations for GAAP profit, reporting $1.04 per share against analyst estimates of $0.01. Agilon raised its full-year revenue guidance to $5.82 billion at the midpoint, up from $5.74 billion previously. The company's adjusted EBITDA of $70 million significantly beat analyst estimates of $19.95 million. The platform provider for value-based care models reported 549,000 customers in the quarter, up from 426,000 in the previous quarter. Operating margin improved to 0.8%, compared with negative 8.3% in the same quarter last year.

Agilon Health (NYSE:AGL) releases earnings results, beats estimates by $0.92 EPS. August 5, 2026 Key points. * Agilon Health beat quarterly earnings expectations: The company reported $1.04 in EPS, exceeding the $0.12 consensus estimate by $0.92, while revenue reached $1.49 billion versus expectations of $1.45 billion. * Shares surged 12.4% to $106.55 following the earnings release, although the stock remains highly volatile, with a beta of 3.01 and a 52-week range of $7.48 to $133.04. * Analyst sentiment remains mixed despite several upgrades: Agilon has five Buy, six Hold, and three Sell ratings, producing a consensus rating of Hold and an average price target of $66.50. * MarketBeat previews the top five stocks to own by September 1st. Agilon Health (NYSE:AGL - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.92, FiscalAI reports. Agilon Health had a negative return on equity of 146.03% and a negative net margin of 6.09%.The business had revenue of $1.49 billion during the quarter, compared to the consensus estimate of $1.45 billion. Agilon Health stock up 12.4%. AGL stock traded up $11.77 during mid-day trading on Wednesday, reaching $106.55. The company had a trading volume of 1,112,918 shares, compared to its average volume of 354,822. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of -4.94 and a beta of 3.01. Agilon Health has a 52 week low of $7.48 and a 52 week high of $133.04. The stock has a 50 day simple moving average of $106.46 and a two-hundred day simple moving average of $54.68. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.04 and a quick ratio of 1.04. Analyst ratings changes. A number of research firms have weighed in on AGL. Jefferies Financial Group raised Agilon Health from a "hold" rating to a "buy" rating and upped their price target for the stock from $27.50 to $48.00 in a research report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft raised shares of Agilon Health from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $33.00 to $49.00 in a research report on Thursday, May 7th. Wells Fargo & Company restated an "overweight" rating and set a $141.00 target price (up from $72.00) on shares of Agilon Health in a report on Monday, July 13th. JPMorgan Chase & Co. downgraded shares of Agilon Health from a "neutral" rating to an "underweight" rating and set a $21.00 target price for the company. in a research report on Monday, May 4th. Finally, Benchmark reissued a "buy" rating and set a $95.00 price target (up from $13.00) on shares of Agilon Health in a research report on Thursday, May 21st. Five research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $66.50. Discover more Financial News Subscription Stock Profit Calculator Dividend Screener Tool Hedge funds weigh in on Agilon Health. Several hedge funds and other institutional investors have recently made changes to their positions in the company. CIBC Bancorp USA Inc. bought a new stake in Agilon Health during the third quarter worth $34,000. Tower Research Capital LLC TRC grew its position in shares of Agilon Health by 214.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 37,079 shares of the company's stock valued at $85,000 after acquiring an additional 25,270 shares during the period. Prudential Financial Inc. increased its stake in shares of Agilon Health by 70.7% during the 2nd quarter. Prudential Financial Inc. now owns 40,880 shares of the company's stock worth $94,000 after purchasing an additional 16,928 shares during the last quarter. LPL Financial LLC increased its stake in shares of Agilon Health by 213.4% during the 4th quarter. LPL Financial LLC now owns 44,055 shares of the company's stock worth $30,000 after purchasing an additional 30,000 shares during the last quarter. Finally, WINTON GROUP Ltd bought a new stake in shares of Agilon Health in the 2nd quarter valued at about $106,000. Agilon Health company profile. Agilon Health NYSE: AGL is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery. Agilon's platform encompasses data analytics, care management, patient engagement tools and population health programs. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Agilon Health, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilon Health wasn't on the list. While Agilon Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom.